We have located links that may give you full text access.
JOURNAL ARTICLE
REVIEW
[Current Status and Prospect of T790M Mutation in Non-small Cell Lung Cancer].
Zhongguo Fei Ai za Zhi = Chinese Journal of Lung Cancer 2017 March 21
Targeted therapy with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKIs) is regarded as the main accepted first-line treatment on EGFR mutation in non-small cell lung cancer (NSCLC). Although targeted therapy for the first and two generation of TKIs may lead to longer progression-free survival (PFS) and better tolerance for patients, the long-term treatment will inevitably lead to drug resistance. Among them, more than 50% of acquired resistance is associated with T790M mutation. The latest guidelines from the National Comprehensive Cancer Network (NCCN) have been proposed that the three generation of TKI (Osimertinib) can be used in first-line TKI therapy progress with detecting T790M mutations in patients. Encouraged by the treatment time of the median PFS up to 13 months and sequential EGFR-TKIs treatment which brought from the three generation of TKI, we also face serious challenges, such as how to achieve the detecting and the dynamic monitoring of T790M, the research progress, mechanism of drug resistance and subsequent treatment of the existing three generation TKI etc. This article will revolve around the above hot issues.
Full text links
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app